Association of anticoagulation dose and survival in hospitalized COVID‐19 patients: A retrospective propensity score‐weighted analysis

Simple item page
dc.citation.journalTitleEuropean Journal of Haematology
dc.contributor.authorIonescu, Filip
dc.contributor.authorJaiyesimi, Ishmael
dc.contributor.authorPetrescu, Ioana
dc.contributor.authorLawler, Patrick R.
dc.contributor.authorCastillo, Edward
dc.contributor.authorMunoz‐Maldonado, Yolanda
dc.contributor.authorImam, Zaid
dc.contributor.authorNarasimhan, Mangala
dc.contributor.authorAbbas, Amr E.
dc.contributor.authorKonde, Anish
dc.contributor.authorNair, Girish B.
dc.date.accessioned2020-12-09T14:59:08Z
dc.date.available2020-12-09T14:59:08Z
dc.date.issued2020
dc.description.abstractBackground: Hypercoagulability may contribute to COVID‐19 pathogenicity. The role of anticoagulation (AC) at therapeutic (tAC) or prophylactic doses (pAC) is unclear. Objectives: We evaluated the impact on survival of different AC doses in COVID‐19 patients. Methods: Retrospective, multi‐center cohort study of consecutive COVID‐19 patients hospitalized between March 13 and May 5, 2020. Results: A total of 3480 patients were included (mean age, 64.5 years [17.0]; 51.5% female; 52.1% black and 40.6% white). 18.5% (n = 642) required intensive care unit (ICU) stay. 60.9% received pAC (n = 2121), 28.7% received ≥3 days of tAC (n = 998), and 10.4% (n = 361) received no AC. Propensity score (PS) weighted Kaplan‐Meier plot demonstrated different 25‐day survival probability in the tAC and pAC groups (57.5% vs 50.7%). In a PS–weighted multivariate proportional hazards model, AC was associated with reduced risk of death at prophylactic (hazard ratio [HR] 0.35 [95% confidence interval {CI} 0.22‐0.54]) and therapeutic doses (HR 0.14 [95% CI 0.05‐0.23]) compared to no AC. Major bleeding occurred more frequently in tAC patients (81 [8.1%]) compared to no AC (20 [5.5%]) or pAC (46 [2.2%]) subjects. Conclusions: Higher doses of AC were associated with lower mortality in hospitalized COVID‐19 patients. Prospective evaluation of efficacy and risk of AC in COVID‐19 is warranted.
dc.identifier.citationIonescu, Filip, Jaiyesimi, Ishmael, Petrescu, Ioana, et al.. "Association of anticoagulation dose and survival in hospitalized COVID‐19 patients: A retrospective propensity score‐weighted analysis." <i>European Journal of Haematology,</i> (2020) Wiley: https://doi.org/10.1111/ejh.13533.
dc.identifier.doihttps://doi.org/10.1111/ejh.13533
dc.identifier.urihttps://hdl.handle.net/1911/109634
dc.language.isoeng
dc.publisherWiley
dc.rightsThis is an author's peer-reviewed final manuscript, as accepted by the publisher. The published article is copyrighted by Wiley.
dc.titleAssociation of anticoagulation dose and survival in hospitalized COVID‐19 patients: A retrospective propensity score‐weighted analysis
dc.typeJournal article
dc.type.dcmiText
dc.type.publicationpost-print
Files
Original bundle
Now showing 1 - 1 of 1
Thumbnail Image
Name:
AJH-20-1685_Proof_hi-copy.pdf
Size:
1.32 MB
Format:
Adobe Portable Document Format
Description:
Download
Collections
Rice Coronavirus Research